The inhibitor of the serine/threonine kinase Pim-1 “SGI-1776” was identified as a promising therapy, corroborating experimental data which suggest that inhibition of the Pim-1/NFATc1/NLRP3 pathway ameliorates nephritis in lupus mouse models [22]. This evidence concerns the gene NFATC1 and nephritis.